SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.

MLA

Deng, Ling, et al. “SF3A2 Promotes Progression and Cisplatin Resistance in Triple-Negative Breast Cancer via Alternative Splicing of MKRN1.” Science Advances, vol. 10, no. 14, Apr. 2024, p. eadj4009. EBSCOhost, https://doi.org/10.1126/sciadv.adj4009.

APA

Deng, L., Liao, L., Zhang, Y.-L., Yang, S.-Y., Hu, S.-Y., Andriani, L., Ling, Y.-X., Ma, X.-Y., Zhang, F.-L., Shao, Z.-M., & Li, D.-Q. (2024). SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1. Science Advances, 10(14), eadj4009. https://doi.org/10.1126/sciadv.adj4009

Chicago

Deng, Ling, Li Liao, Yin-Ling Zhang, Shao-Ying Yang, Shu-Yuan Hu, Lisa Andriani, Yun-Xiao Ling, et al. 2024. “SF3A2 Promotes Progression and Cisplatin Resistance in Triple-Negative Breast Cancer via Alternative Splicing of MKRN1.” Science Advances 10 (14): eadj4009. doi:10.1126/sciadv.adj4009.